Medical Professionals

下面列出了当前开展的临床试验。

根据地点、状态和其他条件对此研究列表进行过滤。

1. A Study to Evaluate the Characteristics and Role of Mucosal Microbiome after Treatment of Clostridium-difficile Infection

   Rochester, Minn.

   The purpose of this study is to characterize the mucosal microbiome in patients who have recently been treated for Clostridium-difficile Infection (CDI) in comparison to that of control population to determine the effect of the mucosal associated microbiome on outcome of CDI.
   
    

2. A Safety Study of SEA-TGT in Patients With Advanced Cancer

   Rochester, Minn.

   This trial will look at a drug called SGN-TGT to find out whether it is safe for patients with solid tumors and lymphomas. It will study SGN-TGT to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether SGN-TGT works to treat solid tumors and lymphomas. The study will have three groups or "parts." Part A of the study will find out how much SGN-TGT should be given to patients. Part B will use the dose found in Part A to find out how safe SGN-TGT is and if it works to treat solid tumors and lymphomas. Part C will study how well SGN-TGT with a PD-(L)1 inhibitor works to treat solid tumors and lymphomas. PD-(L)1 inhibitors are drugs that can be used to treat these types of cancer.

3. Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients

   Scottsdale/Phoenix, Ariz., Rochester, Minn.

   This is a phase II multi-center study of nab-paclitaxel, gemcitabine and cisplatin (NGC triple regimen) as preoperative therapy in potentially resectable pancreatic cancer patients. DISEASE STATE - Potentially operable or borderline resectable pancreatic adenocarcinoma as assessed by standard CT criteria and histologically confirmed. - Staging by pancreatic protocol, helical abdominal computed tomography (with contrast) or MRI (with contrast) required (endoscopic ultrasound is not required). - No evidence of metastatic disease. Lymphadenopathy (defined as nodes measuring >1 cm in short axis) outside the surgical basin (i.e., para-aortic, peri-caval, celiac axis, or distant nodes) is considered M1 (unless nodes are biopsied and are negative, then enrollment can be considered after review with the study PI). Potentially Resectable Pancreatic Cancer - No involvement of the celiac artery, common hepatic artery, and superior mesenteric artery (SMA) and, if present, replaced right hepatic artery. - No involvement or <180° interface between tumor and vessel wall of the portal vein and/or superior mesenteric vein (SMV-PV) and patent portal vein/splenic vein confluence. - For tumors of the body and tail of the pancreas, involvement of the splenic artery and vein of any degree is considered resectable disease. Borderline Resectable Pancreatic Cancer - Tumor-vessel interface ≥180° of vessel wall circumference, and/or reconstructible occlusion of the SMV-PV. - Tumor-vessel interface <180° of the circumference of the SMA. - Tumor-vessel interface <180° of the circumference of the celiac artery. - Reconstructible short-segment interface of any degree between tumor and hepatic artery.

4. Fecal Microbiota Transplant National Registry

   Rochester, Minn.

   A national data registry of patients receiving fecal microbiota transplantation (FMT) or other gut-related-microbiota products designed to prospectively assess short and long-term safety and effectiveness.

5. A Study of OX40L As a Functional Biomarker for Liver Fibrosis

   Scottsdale/Phoenix, Ariz.

   The primary purpose of this study is to investigate whether the abundance of OX40L expression is associated with the development of hepatic fibrosis.

6. Safety and Effectiveness of Esophageal Self Dilation for Benign Refractory Esophageal Stricture Management

   Rochester, Minn., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to assess the clinical effectiveness of ESDT for patients with RBES defined as the number of endoscopic interventions  6 months following serial dilation.

7. A Study to Analyze Onvansertib Treatment in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

   Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

   This study aims to assess the efficacy of onvansertib in combination with nanoliposomal irinotecan (nal-IRI), leucovorin, and fluorouracil (5-FU) for treatment of participants with histologically confirmed metastatic pancreatic ductal adenocarcinoma (PDAC).

8. The Influence of Diet on Gut Microbiotas

   Rochester, Minn.

   The purpose of this research is to determine if different diets have different effects on the micribiome and inflammation of your colon.

9. Evaluation of Outcomes in Metastatic Gastric and Esophageal Carcinoma in Relation to Immunotherapy

   Rochester, Minn.

   The purpose of this study is:

   • To assess the efficacy of treatment with checkpoint inhibitors (Pembrolizumab or Nivolumab) in metastatic gastric and esophageal carcinoma through retrospective chart review.
   • To explore if response to checkpoint inhibitors is dependent on biomarkers on tumor tissue.

10. A Study of MT-5111 in HER2-positive Solid Tumors

    Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz.

    The purpose of this study is to evaluate dose escalation and expansion of MT-5111 (a recombinant fusion protein) in subjects with HER2-positive solid tumors.